Auxilium Pharmaceuticals (AUXL) Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p < 0.001) in CORD I Pivotal Phase III Study for Dupuytren's Contracture XIAFLEX Also Meets ...
Common activities for patients with Dupuytren's such as those at the workplace (eg, manual labor, wearing gloves) or at home (eg, washing, dressing) can be signicantly affected, posing a threat to ...
Please provide your email address to receive an email when new articles are posted on . Injectable collagenase clostridium histolyticum has revolutionized treatment for Dupuytren’s contracture. In ...
Please provide your email address to receive an email when new articles are posted on . BOSTON — Despite more pain and larger skin ruptures directly after treatment among patients who received ...
MALVERN, Pa., Nov. 20, 2024 /CNW/ -- Endo, Inc. ("Endo") (OTCQX: NDOI) announced today that John Elway will share an update about his Dupuytren's contracture patient journey, including his treatment ...
MALVERN, Pa., Feb. 3 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL), a specialty biopharmaceutical company, just announced that it has received marketing approval from the U.S. Food and ...
-- Endo presents encore data of research evaluating the impact of PD on erectile function and female partners, as well as the efficacy of XIAFLEX® treatment -- DUBLIN, May 19, 2015 /PRNewswire/ -- ...
DUBLIN, Jan. 24, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that the peer-reviewed Journal of Hand Surgery Global Open published Collagenase Clostridium Histolyticum for ...
DUBLIN, Jan. 14, 2026 /PRNewswire/ -- Keenova Therapeutics plc announced today that it will present a live treatment procedure with XIAFLEX ® (collagenase clostridium histolyticum) for Dupuytren's ...
September 17, 2009 — The US Food and Drug Administration (FDA)'s Arthritis Advisory Committee voted unanimously (12 to 0) yesterday to recommend approval of collagenase clostridium histolyticum ...
DUBLIN, June 5, 2023 /PRNewswire/ -- Endo International plc (ENDPQ) announced today that post-hoc data from two Phase 3 studies of XIAFLEX ® (collagenase clostridium histolyticum, or CCH, injection ...